[{"orgOrder":0,"company":"Acerta Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Acerta Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Acerta Pharma \/ Acerta Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Acerta Pharma \/ Acerta Pharma"},{"orgOrder":0,"company":"Acerta Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"||Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Approved FDF","graph3":"Acerta Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Acerta Pharma \/ Acerta Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Acerta Pharma \/ Acerta Pharma"},{"orgOrder":0,"company":"Acerta Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acerta Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Acerta Pharma \/ Acerta Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Acerta Pharma \/ Acerta Pharma"},{"orgOrder":0,"company":"Acerta Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Acerta Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Acerta Pharma \/ Acerta Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Acerta Pharma \/ Acerta Pharma"},{"orgOrder":0,"company":"Acerta Pharma","sponsor":"Acerta Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase II","graph3":"Acerta Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acerta Pharma \/ Acerta Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Acerta Pharma \/ Acerta Pharma"},{"orgOrder":0,"company":"Acerta Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase I","graph3":"Acerta Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Acerta Pharma \/ Acerta Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Acerta Pharma \/ Acerta Pharma"},{"orgOrder":0,"company":"Acerta Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Undisclosed","graph2":"Phase I","graph3":"Acerta Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Acerta Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Acerta Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Acerta Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Undisclosed","graph2":"Phase I","graph3":"Acerta Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Acerta Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Acerta Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Acerta Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Undisclosed","graph2":"Phase I","graph3":"Acerta Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Acerta Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Acerta Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Acerta Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Undisclosed","graph2":"Phase I","graph3":"Acerta Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Acerta Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Acerta Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Acerta Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Undisclosed","graph2":"Phase I","graph3":"Acerta Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Acerta Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Acerta Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Acerta Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Undisclosed","graph2":"Phase I","graph3":"Acerta Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Acerta Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Acerta Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Acerta Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Undisclosed","graph2":"Phase I","graph3":"Acerta Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Acerta Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Acerta Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Acerta Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Acerta Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acerta Pharma \/ Acerta Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Acerta Pharma \/ Acerta Pharma"},{"orgOrder":0,"company":"Acerta Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Acerta Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Acerta Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Acerta Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Acerta Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase III","graph3":"Acerta Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acerta Pharma \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Acerta Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"Acerta Pharma","sponsor":"Ascentage Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Lisaftoclax","moa":"||Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Acerta Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acerta Pharma \/ Ascentage Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Acerta Pharma \/ Ascentage Pharma"},{"orgOrder":0,"company":"Acerta Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Undisclosed","graph2":"Phase I","graph3":"Acerta Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Acerta Pharma \/ Acerta Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Acerta Pharma \/ Acerta Pharma"},{"orgOrder":0,"company":"Acerta Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Acerta Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acerta Pharma \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Acerta Pharma \/ AstraZeneca"}]
Find Clinical Drug Pipeline Developments & Deals by Acerta Pharma
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
